LPL gene variants affect apoC-III response to combination therapy of statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia

類似資料

• Interaction between SNPs in the RXRA and near ANGPTL3 gene region inhibits apoB reduction after statin-fenofibric acid therapy in individuals with mixed dyslipidemia
  著者:: Ma, Li, 等
  出版事項: (2012)
• Rare LPL gene variants attenuate triglyceride reduction and HDL cholesterol increase in response to fenofibric acid therapy in individuals with mixed dyslipidemia
  著者:: Gao, Feng, 等
  出版事項: (2014)
• Variants in the APOA5 gene region and the response to combination therapy with statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia
  著者:: Brautbar, Ariel, 等
  出版事項: (2011)
• Rare APOA5 promoter variants associated with paradoxical HDL cholesterol decrease in response to fenofibric acid therapy
  著者:: Brautbar, Ariel, 等
  出版事項: (2013)
• Antisense inhibition of apoB synthesis with mipomersen reduces plasma apoC-III and apoC-III-containing lipoproteins
  著者:: Furtado, Jeremy D., 等
  出版事項: (2012)